180 results about "Tissue factor" patented technology

The present teachings relate to a method of assessing the probability of a major adverse cardiovascular or cerebrovascular event in a human. The method can include measuring a concentration, in a blood-based sample of a human, of a set of analytes, for example, alpha-fetoprotein, cancer antigen 125, glutathione S-transferase, and tissue factor. The method also can include determining a MACCE index for the set of analytes and identifying the human as having an increased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is greater than zero, or a decreased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is less than or equal to zero.

This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

The invention belongs to biology technology field, which concretely refers to controlled release tissue factor path inhibitor (LTFPI) and the manufacturing method, and the application. The invention analyzes and experiments the biology information science and structure molecular biology science of tissue factor path inhibitor (TFPI) and its acceptor low density lipoprotein acceptor correspondent protein (LRP), it ascertains the part where the TFPI carboxy end combines with LRP and is eliminated. It designs TFPI carboxy end mutant, which is recombined with primary nucleus or eukarya expressing carrier after constructing LTFPI gene through PCR location, it converts bacillus coli or bici yeast, sifts the high expression project fungus. The primary project fungus are yeasted and expanded, crushed, then they are centrifugated and collects the inclusion body, purifies the LTFPI through molecular sift and ion interchanging two-step method; the eukarya project fungus are carried on with two-step purifying directly. The half-life are prolonged, it has good pour-depressant function.

The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.

The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl₂. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

The invention relates to the field of quality control of blood coagulation testing items and provides a 3-level thrombelastogram quality control product. The quality control product is prepared by the following steps: respectively mixing pig blood with 3 different concentrations of sodium citrate, centrifuging, taking blood plasma, respectively adding a coagulation activator and a tissue factor and lyophilizing to prepare a powdery quality control product I, adding a coagulation activator and lyophilizing to prepare a powdery quality control product II, and adding a coagulation activator and human lyophilized platelets and lyophilizing to prepare a powdery quality control product III. The 3-level thrombelastogram quality control product provided by the invention is shaped as a lyophilized powder, can be used to monitor R and MA values simultaneously, is better used for quality control of an thromboelastography instrument and a thrombelastogram detection kit, is fast to detect, has accurate results and is simple to operate.

The invention discloses a hepaplastin test determination kit and a preparation method thereof. Through combination of a buffer solution system a containing multiple effective components, plasma without blood coagulation factors VII, II, X and IX, a buffer system b, rabbit brain powder and tissue factor ester, the hepaplastin test determination kit improves reagent stability. A hepaplastin test determination reagent with good accuracy, good repeatability and good effects is further obtained.

The invention discloses an activated coagulation detection reagent and an application thereof. The reagent is prepared from the following components: an activating agent, mixed phospholipid and composite stabilizer, wherein the activating agent comprises one or more of kaolin, porcellanite, diatomite, ellagic acid, silicon dioxide and a tissue factor, and the composite stabilizer comprises a polymer, an anticorrosive agent and a water soluble antioxidant. The detection reagent does not use a buffer solution adopted in the prior art and does not use normal saline. By combining the activating agent, the mixed phospholipid and the composite stabilizer, the composite stabilizer is used as a solution environment, so that the stability of the detection reagent can be guaranteed. The detection reagent can effectively avoid the adverse influence of the buffer solution used in the prior art for promoting the hydrolysis of the phospholipid; and moreover, the activated coagulation detection reagent is low in cost, good in effect and stable in properties.

Tissue factor-bearing yeast derived microvesicles comprising a yeast membrane and a tissue factor protein, or a fragment thereof, or a tissue factor protein or a fragment thereof fused to another peptide as a fusion protein having pro-coagulant activity are disclosed. Said products can be used as pro-coagulant agents in the treatment of hemorrhages in a subject.

The invention relates to a liquid-phase chip kit for acute coronary syndrome and a preparation method for the same. A liquid-phase chip mainly comprises microspheres coated with oxidized low density lipoprotein (ox-LDL), soluble CD40 ligand (sCD40L), matrix metallopeptidase 9 (MMP-9), tissue factor (TF), omentin and endogenous secretory receptor of advanced glycation end products (esRAGE) capture antibody respectively, detection antibodies labelled by biotin, and streptavidin phycoerythrin. The liquid-phase chip provided by the invention has the advantages of being high in detection efficiency, low in the quantity of the needed samples, strong in specificity, high in sensitivity, rapid and accurate in detection, and the like. Simultaneously, the chip reflects a protective factor level and an injury factor level in an organism, so that the risk stratification and prognosis conditions of a patient can be much comprehensively assessed. Simultaneously, the preparation method disclosed by the invention is simple and practicable, and good in stability, various process parameters such as the quantities of the microspheres and the antibodies, and the reaction process in the technical scheme of the preparation method are obtained on the basis of lots of experiments, and are the optimal parameter values of the preparation process.

The invention discloses a liquid ready-to-use prothrombin time detection reagent, which comprises buffer, synthetic phospholipid, recombinant rabbit tissue factor, surfactant and stabilizer. The synthetic phospholipid consists of phosphatidylserine, phosphatidylcholine and Cholesterol composition. The invention utilizes rabbit recombinant factors and synthetic phospholipids, selects the components of the synthetic phospholipids, and optimizes the stabilizer to prepare prothrombin time detection reagents, which can be used immediately after opening the bottle without reconstitution. The reagent overcomes the problem that the batch-to-batch difference of existing prothrombin time detection reagents is difficult to control, and has high sensitivity, good stability, small batch-to-batch difference, easy quality control, and easy production.

The invention provides the expression and the purification of a recombinant fusion protein, particularly a fusion protein of the tumor blood vessel targeted polypeptide and tissue factor and a preparation method and application thereof. The preparation method of the fusion protein of the tumor blood vessel targeted polypeptide and tissue factor comprises the following steps: designing primers, carrying out PCR (polymerase chain reaction) to amplify an recombinant gene of the fusion protein EG3287-tTF, guiding the recombinant gene of the fusion protein EG3287-tTF into a carrier, guiding a recombinant carrier into a host cell, constructing a recombinant engineering bacteria for expressing the fusion protein EG3287-tTF, fermenting to culture, and separating and purifying fermentation liquor to obtain the fusion protein of the tumor blood vessel targeted polypeptide and tissue factor. The targeted antitumor fusion protein EG3287-tTF is constructed, a novel tTF derivative with the antitumor advantage of the tTF and the targeting effect is obtained, the antitumor effect of the tTF is improved, and a foundation is laid to the development of a novel medicament for the targeted therapy of the tumor blood vessel.

Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidyl serine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

The present invention relates to a human recombinant tissue factor, its construction, expression and purification method and application. Said method includes the following steps: recombining TF gene fragment obtained from human placenta with phoA plasmid, constructing plasmid vector pTF243, transforming it into colibacillus MM294, screening and obtaining engineering strain, inoculating said strain into culture medium to directly make fermentation and expression to obtain bacterial liquor, then using Q-Sepharose Fast Flow matrix to make the bacterial liquor under the process of ion exchange chromatography, then pass through TF monoclonal antibody immunoaffinity chromatographic column to make adsorption and elution so as to obtain the rhTF243 protein.

DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.

The invention discloses an electrochemical method-based PT (Prothrombin Time) test card and a preparation method thereof. The electrochemical method-based PT test card is formed by an electric conduction substrate, a chemical reagent and the like, wherein the chemical reagent is specifically prepared from the main components of tissue factors, phospholipid and the like. The electrochemical method-based PT test card prepared by the invention is capable of realizing PT detection on fingertip blood or a blood sample which is not subjected to blood coagulation treatment, and has the advantages of high accuracy, good repeatability and the like; the preparation method is simple, has low technical requirements on equipment and operators, is strong in operability and has a wide application prospect in the fields of clinical examination and the like.

The invention relates to a preparation method for prothrombin time determination reagent (PT reagent), comprising the following steps. Cow or sheep tissue factor with the purity of more than 90% is prepared by the genetic engineering method, phospholipid is dispersed in phosphate buffer solution containing surfactant, and then the tissue factor and the phospholipid are mixed and sufficiently combined, and finally, C18 resin is adopted to adsorb and separate the surfactant, and the PT reagent product is obtained after freeze-drying. The preparation method is stable in technique and strong in operability, and further, the obtained PT reagent has better stability, sensitiveness and fewer impurities, and the quality can be easily ensured.